Syndax Pharmaceuticals
SNDX
177 hedge funds and large institutions have $1.95B invested in Syndax Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 82 increasing their positions, 42 reducing their positions, and 34 closing their positions.
95% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 42
89% more capital invested
Capital invested by funds: $1.03B → $1.95B (+$920M)
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
10.06% more ownership
Funds ownership: 102.21% → 112.28% (+10%)
1% more funds holding
Funds holding: 175 → 177 (+2)
6% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 34
6% more call options, than puts
Call options by funds: $15.7M | Put options by funds: $14.9M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$42.7M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$31.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$28.8M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$25.6M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$25.3M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$35.3M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$34.7M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$32.6M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$17.9M |
| 5 |
CC
Commodore Capital
New York
|
-$13.9M |
SNDX Hedge Fund Activity: Q4 2023 in Review
177 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2023, worth a combined $1.95B — up 89% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new SNDX positions and 34 closed out — a net gain of 2 holders — while 82 added to existing stakes and 42 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $42.7M. The largest seller was Jennison Associates, cutting an estimated $35.3M.
- 177 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2023, up from 175 in Q3 2023.
- Funds reported $1.95B of Syndax Pharmaceuticals stock for Q4 2023, up 89% quarter-over-quarter.
- 36 funds opened new Syndax Pharmaceuticals positions in Q4 2023 and 34 closed out, a net change of +2 holders.
- The largest Syndax Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $42.7M added.
- The largest Syndax Pharmaceuticals seller in Q4 2023 was Jennison Associates, an estimated $35.3M sold.
Based on aggregated 13F filings for Q4 2023.